Skip to contentC
Cocrystal Pharma, Inc.
C
COCPCocrystal Pharma, Inc. Q2 2026 · 10-Q
Revenue$105.00K$105.00Kno prior Q2 2025 on file Net Income-$3.16M-$3.16MN/M vs Q2 2025 EPS Diluted-$0.23-$0.23N/M vs Q2 2025 Operating Income-$3,184,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cocrystal Pharma, Inc. · CIK 1412486 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-3032.4%
Net margin-3013.3%
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end